Akèy › Limfòm Burkitt › Kalifòni › San Francisco
Etid klinik pou Limfòm Burkitt nan San Francisco, CA
8 etid pou Limfòm Burkitt ap chèche patisipan nan sit nan ak bò kote San Francisco (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
Ap rekriteFaz 2
- UCSF Medical Center-Mission Bay, San Francisco
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
Ap rekriteFaz 3
- Kaiser Permanente-San Francisco, San Francisco
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
Ap rekriteFaz 2
- UCSF Medical Center-Mission Bay, San Francisco
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
Ap rekriteFaz 2
- UCSF Medical Center-Mission Bay, San Francisco
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
Ap rekriteFaz 3
- UCSF Medical Center-Mission Bay, San Francisco
Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
Ap rekriteFaz 2
- UCSF School of Medicine, San Francisco
Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma
Ap rekriteFaz 1
- University of California, San Francisco, San Francisco
The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL
Ap rekriteFaz 2
- UCSF, San Francisco
Etid Limfòm Burkitt nan lòt vil
- Houston, TX21 etid
- Philadelphia, PA16 etid
- Milwaukee, WI16 etid
- Chicago, IL15 etid
- Cincinnati, OH13 etid
- New York City, NY13 etid
- Atlanta, GA12 etid
- Aurora, CO11 etid
- Seattle, WA11 etid
- Durham, NC10 etid
- Boston, MA10 etid
- Kansas City, MO10 etid
Lòt etid nan San Francisco
- Kansè pwostat45 etid
- Kansè nan tete43 etid
- Kansè Poumon ki pa ti selil36 etid
- Kansè (tout kalite)35 etid
- Ensifizyans kadyak29 etid
- Kansè Metastatik28 etid
- Kansè poumon22 etid
- Melanom22 etid
- Kansè pankreyas20 etid
- Kansè ovè19 etid
- Kansè kolorektal18 etid
- Maladi kadyovaskilè18 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.